Immunological impact of an additional early measles vaccine in Gambian children: Responses to a boost at 3 years

Njie-Jobe, Jainaba; Nyamweya, Samuel; Miles, David J. C.; Sande, Marianne A. B. van der; Zaman, Syed M A; Touray, Ebrima; Hossin, Safayet; Adetifa, Jane U.; Palmero, Melba S.; Burl, Sarah; Jeffries, David; Rowland‐Jones, Sarah; Flanagan, Katie L.; Jaye, Assan; Whittle, Hilton

doi:10.1016/j.vaccine.2012.01.083

Cited by 33 publications

(32 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, MMR was given at 12 months of age, while in many developing countries a MCV is given at 9 months of age or earlier. While age at first MCV does not influence cellular vaccine responses, younger age is associated with lower antibody responses, faster waning and lower avidity of antibodies . In contrast, MCV were observed to have a stronger effect on the reduction in all‐cause mortality when given at a younger age .…”

Section: Discussionmentioning

confidence: 84%

The immunomodulatory effects of measles‐mumps‐rubella vaccination on persistence of heterologous vaccine responses

et al. 2019

View full text Add to dashboard Cite

It is proposed that measles‐containing vaccines have immunomodulatory effects which include a reduction in all‐cause childhood mortality. The antibody response to heterologous vaccines provides a means to explore these immunomodulatory effects. This is the first study to investigate the influence of measles‐mumps‐rubella (MMR) vaccine on the persistence of antibodies to a broad range of heterologous infant vaccinations given in the first year of life. In total, 319 children were included in the study. All infants received routine vaccinations at 6 weeks, 4 and 6 months of age. At 12 months of age, 212 children were vaccinated with MMR and Haemophilus influenzae type b‐meningococcus C (Hib‐MenC) vaccines while the remaining 99 children had not yet received these vaccines. In the MMR/Hib‐MenC‐vaccinated group, blood was taken 28 ± 14 days after receiving these vaccines. Antibodies against diphtheria, tetanus, pertussis [pertussis toxin (PT), filamentous hemagglutinin, pertactin], poliomyelitis (type 1, 2, 3) and 13 pneumococcal serotypes were measured. Seroprotection rates and geometric mean antibody concentrations were compared between MMR/MenC‐Hib‐vaccinated and MMR/MenC‐Hib‐naïve participants. In the final analysis, 311 children were included. Seroprotection rates were lower in MMR/Hib‐MenC‐vaccinated children against PT and pneumococcal serotype 19A. After adjustment for prespecified factors, MMR/Hib‐MenC‐vaccinated infants had significantly higher antibody concentrations against tetanus (likely explained by a boosting effect of the carrier protein, a tetanus toxoid), while for the other vaccine antigens there was no difference in antibody concentrations between the two groups. MMR vaccination given at 12 months of age in a developed country does not significantly influence antibody concentrations to heterologous vaccines received in the first year of life.

show abstract

Section: Discussionmentioning

confidence: 84%

The immunomodulatory effects of measles‐mumps‐rubella vaccination on persistence of heterologous vaccine responses

et al. 2019

View full text Add to dashboard Cite

show abstract

“…This means that the amount of maternal antibodies passively transferred to the infant is lower in populations where vaccination programmes are available [16,19,20,25,30,[32][33][34]60]. Therefore, infants are likely to become susceptible to infection earlier than when the mother's antibodies were from wild-type infection [6,20,25,33,60,99]. It was also argued by some that infants from developing countries lose passive immunity quicker than those from developed countries due to poor nutrition and general health [20,25].…”

Section: Major Findings Of the Reviewmentioning

confidence: 99%

“…Six of the measles surveys [10,59,60,77,86,89] evaluating vaccination programmes compared the efficacy of different vaccines and/or vaccine schedules. Of these six, two [59,86] also evaluated the rubella antibody response to vaccination.…”

mentioning

confidence: 99%

A 16-year review of seroprevalence studies on measles and rubella

Dimech¹,

Mulders

2016

Vaccine

View full text Add to dashboard Cite

“…Lower antibody concentrations persist after the second dose of measles vaccine (49,50). In contrast, age at first measles vaccination does not influence cellular responses: no differences in in vitro T cell proliferation in response to measles virus were observed after starting vaccination at 4, 6, 9, or 12 months (30,37,38,51).…”

Section: Introductionmentioning

confidence: 97%

Factors That Influence the Immune Response to Vaccination

2019

View full text Add to dashboard Cite

SUMMARYThere is substantial variation between individuals in the immune response to vaccination. In this review, we provide an overview of the plethora of studies that have investigated factors that influence humoral and cellular vaccine responses in humans. These include intrinsic host factors (such as age, sex, genetics, and comorbidities), perinatal factors (such as gestational age, birth weight, feeding method, and maternal factors), and extrinsic factors (such as preexisting immunity, microbiota, infections, and antibiotics). Further, environmental factors (such as geographic location, season, family size, and toxins), behavioral factors (such as smoking, alcohol consumption, exercise, and sleep), and nutritional factors (such as body mass index, micronutrients, and enteropathy) also influence how individuals respond to vaccines. Moreover, vaccine factors (such as vaccine type, product, adjuvant, and dose) and administration factors (schedule, site, route, time of vaccination, and coadministered vaccines and other drugs) are also important. An understanding of all these factors and their impacts in the design of vaccine studies and decisions on vaccination schedules offers ways to improve vaccine immunogenicity and efficacy.

show abstract

Immunological impact of an additional early measles vaccine in Gambian children: Responses to a boost at 3 years

Cited by 33 publications

References 33 publications

The immunomodulatory effects of measles‐mumps‐rubella vaccination on persistence of heterologous vaccine responses

The immunomodulatory effects of measles‐mumps‐rubella vaccination on persistence of heterologous vaccine responses

A 16-year review of seroprevalence studies on measles and rubella

Factors That Influence the Immune Response to Vaccination

Contact Info

Product

Resources

About